Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC).

Katherine Sanchez; Shu-Ching Chang; Isaac Kim; Maritza Martel; Yaping Wu; William L Redmond; Zhaoyu Sun; Dottie Waddell; Deborah R. Laxague; Brady Bernard; Monil Shah; Walter John Urba; David B. Page

doi:10.1200/JCO.2020.38.15_SUPPL.E12589

Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC).

Katherine Sanchez, Shu-Ching Chang, Isaac Kim, Maritza Martel, Yaping Wu, William L Redmond, Zhaoyu Sun, Dottie Waddell, Deborah R. Laxague, Brady Bernard, Monil Shah, Walter John Urba, David B. Page

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	38
DOIs	https://doi.org/10.1200/JCO.2020.38.15_SUPPL.E12589
State	Published - May 20 2020

Disciplines

Pathology
Medicine and Health Sciences

Access to Document

10.1200/JCO.2020.38.15_SUPPL.E12589License: Unspecified

Cite this

Sanchez, K., Chang, S.-C., Kim, I., Martel, M., Wu, Y., Redmond, W. L., Sun, Z., Waddell, D., Laxague, D. R., Bernard, B., Shah, M., Urba, W. J., & Page, D. B. (2020). Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC). Journal of Clinical Oncology, 38. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.E12589

@article{473c5af687cd465c93a1ea441045b6b8,

title = "Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC).",

author = "Katherine Sanchez and Shu-Ching Chang and Isaac Kim and Maritza Martel and Yaping Wu and Redmond, {William L} and Zhaoyu Sun and Dottie Waddell and Laxague, {Deborah R.} and Brady Bernard and Monil Shah and Urba, {Walter John} and Page, {David B.}",

note = "e12589 Background: There is growing need for surrogate immune-based biomarkers in BC to enhance prediction accuracy and to facilitate comparisons of therapeutic activity in the context of clinical trials. We report mIF as a high-dimensional biomarker that is highly concordant with both PD-L1 (SP142) and sTIL clinical assays (HE), but with greater precision to quantify on-treatment pharmacodynamic effects.",

year = "2020",

month = may,

day = "20",

doi = "10.1200/JCO.2020.38.15_SUPPL.E12589",

language = "American English",

volume = "38",

journal = "Journal of Clinical Oncology",

}

Sanchez, K, Chang, S-C, Kim, I, Martel, M, Wu, Y, Redmond, WL, Sun, Z, Waddell, D, Laxague, DR, Bernard, B, Shah, M, Urba, WJ & Page, DB 2020, 'Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC).', Journal of Clinical Oncology, vol. 38. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.E12589

Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC). / Sanchez, Katherine; Chang, Shu-Ching; Kim, Isaac et al.
In: Journal of Clinical Oncology, Vol. 38, 20.05.2020.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC).

AU - Sanchez, Katherine

AU - Chang, Shu-Ching

AU - Kim, Isaac

AU - Martel, Maritza

AU - Wu, Yaping

AU - Redmond, William L

AU - Sun, Zhaoyu

AU - Waddell, Dottie

AU - Laxague, Deborah R.

AU - Bernard, Brady

AU - Shah, Monil

AU - Urba, Walter John

AU - Page, David B.

N1 - e12589 Background: There is growing need for surrogate immune-based biomarkers in BC to enhance prediction accuracy and to facilitate comparisons of therapeutic activity in the context of clinical trials. We report mIF as a high-dimensional biomarker that is highly concordant with both PD-L1 (SP142) and sTIL clinical assays (HE), but with greater precision to quantify on-treatment pharmacodynamic effects.

PY - 2020/5/20

Y1 - 2020/5/20

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e12589

U2 - 10.1200/JCO.2020.38.15_SUPPL.E12589

DO - 10.1200/JCO.2020.38.15_SUPPL.E12589

M3 - Article

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC).

Disciplines

Access to Document

Other files and links

Cite this